Find Reports

Select Report Type

Reimbursement Review

Displaying 551 - 575 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Alecensaro for Non-Small Cell ...	Alecensaro	Alectinib	pcodr_provfund_alectinib_alecensaro_nsclc.pdf pcodr_alectinib_alecensaro_nsclc_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_fn_cgr.pdf pcodr_alectinib_alecensaro_nsclc_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_ptfdk.pdf pcodr_alectinib_alecensaro_nsclc_clnfdk.pdf pcodr_alectinib_alecensaro_nsclc_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_coi_cln.pdf	Non-Small Cell Lung Cancer	Do not reimburse	Complete	Oct 3, 2016	May 4, 2017	PC0092-000
Tagrisso for Non-Small Cell Lu...	Tagrisso	Osimertinib	pcodr_provfund_10076_osimertinib_tagrisso_nsclc.pdf pcodr_osimertinib_tagrisso_nsclc_fn_rec.pdf pcodr_osimertinib_tagrisso_nsclc_fn_cgr.pdf pcodr_osimertinib_tagrisso_nsclc_fn_egr.pdf pcodr_osimertinib_tagrisso_nsclc_in_rec.pdf pcodr_osimertinib_tagrisso_nsclc_pagfdk.pdf pcodr_osimertinib_tagrisso_nsclc_fdk_azc.pdf pcodr_osimertinib_tagrisso_nsclc_ptfdk.pdf pcodr_osimertinib_tagrisso_nsclc_clnfdk.pdf pcodr_osimertinib_tagrisso_nsclc_coi_pt.pdf pcodr_osimertinib_tagrisso_nsclc_coi_cln.pdf	Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 1, 2016	May 4, 2017	PC0076-000
Propiverine hydrochloride	Mictoryl	Propiverine hydrochloride	cdr_SR0504_Mictoryl.pdf SR0504_Mictoryl_CL Report.pdf SR0504_Mictoryl_PE_Report.pdf SR0504_Mictoryl_PI_Submissions.pdf SR0504_complete_Mictoryl_Apr-21-17-e.pdf	Overactive bladder (OAB)	Reimburse with clinical criteria and/or conditions	Complete	Oct 14, 2016	Apr 19, 2017	SR0504-000
Mifepristone and misoprostol	Mifegymiso	Mifepristone and misoprostol	cdr_SR0502_Mifegymiso.pdf SR0502_complete_Mifegymiso-Apr-20-17-e.pdf SR0502_Mifegymiso_CL_Report.pdf SR0502_Mifegymiso_PE_Report.pdf	Medical termination of pregnancy (gestational age up to 49 days)	Reimburse	Complete	Oct 7, 2016	Apr 18, 2017	SR0502-000
Sarilumab	Kevzara	sarilumab	cdr_SR0503_TBC.pdf SR0503_Kevzara_CL_Report.pdf SR0503_Kevzara_PE_Report.pdf SR0503_Kevzara_PI_Submissions.pdf SR0503_complete_Kevzara-Apr-20-17.pdf	Arthritis, Rheumatoid	Reimburse with clinical criteria and/or conditions	Complete	Oct 12, 2016	Apr 18, 2017	SR0503-000
Caprelsa for Medullary Thyroid...	Caprelsa	Vandetanib	pcodr_provfund_vandetanib_caprelsa_mtc.pdf pcodr_vandetanib_caprelsa_mtc_fn_rec.pdf pcodr_vandetanib_caprelsa_mtc_fn_cgr.pdf pcodr_vandetanib_caprelsa_mtc_fn_egr.pdf pcodr_vandetanib_caprelsa_mtc_in_rec.pdf pcodr_vandetanib_caprelsa_mtc_pagfdk.pdf pcodr_vandetanib_caprelsa_mtc_fdk_sanofig.pdf pcodr_vandetanib_caprelsa_mtc_ptfdk_tcc.pdf pcodr_vandetanib_caprelsa_mtc_coi_tcc.pdf pcodr_vandetanib_caprelsa_mtc_coi_cln.pdf	Medullary Thyroid Cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2016	Mar 30, 2017	PC0090-000
Kyprolis for Multiple Myeloma ...	Kyprolis	Carfilzomib	pcodr_profund_carfilzomib_kyprolis_mm_rel.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_rec.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_cgr.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf pcodr_carfilzomib_kyprolis_mm_rel_in_rec.pdf pcodr_carfilzomib_kyprolis_mm_rel_fdk_amgen.pdf pcodr_carfilzomib_kyprolis_mm_rel_pagfdk.pdf pcodr_carfilzomib_kyprolis_mm_rel_ptfdk_mmc.pdf pcodr_carfilzomib_kyprolis_mm_rel_fdk_cln.pdf pcodr_carfilzomib_kyprolis_mm_rel_coi_mmc.pdf pcodr_carfilzomib_kyprolis_mm_rel_coi_cln.pdf	Multiple Myeloma (relapsed)	Reimburse with clinical criteria and/or conditions	Complete	Sep 9, 2016	Mar 30, 2017	PC0084-000
Reslizumab	Cinqair	Reslizumab	cdr_SR0495_Cinqair.pdf SR0495_complete_Cinqair-Mar-24-17.pdf SR0495_Cinqair_CL_Report.pdf SR0495_Cinqair_PE_Report.pdf SR0495_Cinqair_PI_Submissions.pdf	Asthma, eosinophilic	Reimburse with clinical criteria and/or conditions	Complete	Aug 4, 2016	Mar 22, 2017	SR0495-000
Fluorouracil and Salicylic Aci...	Actikerall	Fluorouracil and Salicylic Acid	cdr_SR0498_Actikerall.pdf SR0498_complete_Actikerall-Mar-24-17.pdf SR0498_Actikerall_CL_Report.pdf SR0498_Actikerall_PE_Report.pdf	Hyperkeratotic actinic keratosis	Reimburse with clinical criteria and/or conditions	Complete	Aug 31, 2016	Mar 22, 2017	SR0498-000
Budesonide	Cortiment	Budesonide	cdr_SR0491_TBC.pdf SR0491_complete_Cortiment-Mar-24-17.pdf SR0491_Cortiment_CL_Report.pdf SR0491_Cortiment_PE_Report.pdf SR0491 Cortiment_PI_Submissions.pdf	Ulcerative Colitis	Do not reimburse	Complete	May 24, 2016	Mar 22, 2017	SR0491-000
Edoxaban	Lixiana NVAF	Edoxaban	cdr_SR0500_Lixiana_NVAF.pdf SR0500_complete_Lixiana-NVAF_Mar-23-17.pdf SR0500_Lixiana_NVAF_CL_Report.pdf SR0500_Lixiana_NVAF_PE_Report.pdf	Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism.	Reimburse with clinical criteria and/or conditions	Complete	Sep 9, 2016	Mar 21, 2017	SR0500-000
glycerol phenylbutyrate	Ravicti	glycerol phenylbutyrate	cdr_SR0497_Ravicti.pdf SR0497_complete_Ravicti_Mar-23-17.pdf SR0497_Ravicti_CL_Report.pdf SR0497_Ravicti_PE_Report.pdf SR0497_Ravicti_PI_Submissions.pdf	Urea cycle disorders	Reimburse with clinical criteria and/or conditions	Complete	Aug 30, 2016	Mar 21, 2017	SR0497-000
ustekinumab	Stelara/Stelara I.V.	ustekinumab	cdr_SR0501_Stelara.pdf SR0501_complete_Stelara_Mar-23-17.pdf SR0501_Stelara_CL_Report.pdf SR0501_Stelara_PE_Report.pdf SR0501_Stelara_PI_Submissions.pdf	Crohn’s disease	Reimburse with clinical criteria and/or conditions	Complete	Sep 12, 2016	Mar 21, 2017	SR0501-000
Zykadia for Non-Small Cell Lun...	Zykadia (Resubmission)	Ceritinib	pcodr_provfund_ceritinib_zykadia_nsclc_resub.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_rec.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_cgr.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_egr.pdf pcodr_ceritinib_zykadia_nsclc_resub_in_rec.pdf pcodr_ceritinib_zykadia_nsclc_resub_pagfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_fdk_novartis.pdf pcodr_ceritinib_zykadia_nsclc_resub_ptfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_clinfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_coi_lcc.pdf pcodr_ceritinib_zykadia_nsclc_resub_coi_clin.pdf	metastatic non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 19, 2016	Mar 21, 2017	PC0094-000
Fentanyl buccal	Fentora	Fentanyl buccal	cdr_SR0494_Fentora.pdf SR0494_Fentora_CL_Report.pdf SR0494_Fentora_PE_Report.pdf SR0494_complete_Fentora_Feb-23-17.pdf	Pain (breakthrough), cancer (adults)	Do not reimburse	Complete	Jul 12, 2016	Feb 21, 2017	SR0494-000
Propranolol oral solution	Hemangiol	Propranolol oral solution	cdr_SR0496_Hemangiol.pdf SR0496_complete_Hemangiol-Feb-23_17.pdf SR0496_Hemangiol_CL_Report.pdf SR0496_Hemangiol_PE_Report.pdf SR0496_Hemangiol_PI_Submissions.pdf	Infantile hemangioma	Reimburse with clinical criteria and/or conditions	Complete	Aug 25, 2016	Feb 21, 2017	SR0496-000
Brivaracetam	Brivlera	Brivaracetam	cdr_SR0484_Brivlera.pdf SR0484_Brivlera_CL_Report.pdf SR0484_Brivlera_PE_Report.pdf sr0484_complete_brivlera_jan-27-17.pdf	Epilepsy, partial-onset seizures	Reimburse with clinical criteria and/or conditions	Complete	Apr 19, 2016	Jan 25, 2017	SR0484-000
Afinitor for Neuroendocrine tu...	Afinitor	Everolimus	pcodr_profund_everolimus_afinitor_net-gil.pdf pcodr_everolimus_afinitor_net-gil_fn_rec.pdf pcodr_everolimus_afinitor_net-gil_fn_cgr.pdf pcodr_everolimus_afinitor_net-gil_fn_egr.pdf pcodr_everolimus_afinitor_net-gil_in_rec.pdf pcodr_everolimus_afinitor_net-gil_pagfdk.pdf pcodr_everolimus_afinitor_net-gil_fdk_novartis.pdf pcodr_everolimus_afinitor_net-gil_fdk_cnets.pdf pcodr_everolimus_afinitor_net-gil_coi_cnets.pdf	Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin	Reimburse with clinical criteria and/or conditions	Complete	May 30, 2016	Dec 1, 2016	PC0083-000
Darzalex for Multiple Myeloma ...	Darzalex	Daratumumab	pcodr_daratumumab_darzalex_mm_fn_rec.pdf pcodr_daratumumab_darzalex_mm_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_fn_egr.pdf pcodr_daratumumab_darzalex_mm_in_rec.pdf pcodr_daratumumab_darzalex_mm_pagfdk.pdf pcodr_daratumumab_darzalex_mm_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_fdk_mc.pdf pcodr_daratumumab_darzalex_mm_fdk_clinician.pdf pcodr_daratumumab_darzalex_mm_coi_mc.pdf pcodr_daratumumab_darzalex_mm_coi_clinician.pdf	Multiple Myeloma	Do not reimburse	Complete	Apr 21, 2016	Dec 1, 2016	PC0079-000
Levofloxacin	Quinsair	Levofloxacin	cdr_SR0493_Quinsair.pdf SR0493_complete_Quinsair_Nov-23-16.pdf SR0493_Quinsair_CL_Report.pdf SR0493_Quinsair_PE_Report.pdf SR0493_Quinsair_PI_Submissions.pdf	Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections	Reimburse with clinical criteria and/or conditions	Complete	May 31, 2016	Nov 21, 2016	SR0493-000
Ibrance for Advanced Breast Ca...	Ibrance Resubmission	Palbociclib	pcodr_profund_10093_palbociclib_ibrance_abc_resub.pdf pcodr_palbociclib_ibrance_resub_abc_fn_rec.pdf pcodr_palbociclib_ibrance_resub_abc_fn_cgr.pdf pcodr_palbociclib_ibrance_resub_abc_fn_egr.pdf pcodr_palbociclib_ibrance_resub_abc_in_rec.pdf pcodr_palbociclib_ibrance_resub_abc_pagfdk.pdf pcodr_palbociclib_ibrance_resub_abc_fdk_pfizer.pdf pcodr_palbociclib_ibrance_resub_abc_ptfdk_rethink.pdf pcodr_palbociclib_ibrance_resub_abc_ptfdk_cbcn.pdf pcodr_palbociclib_ibrance_resub_abc_coi_cbcn-rethink.pdf pcodr_palbociclib_ibrance_resub_abc_coi_clinician.pdf	Advanced breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Jun 10, 2016	Nov 21, 2016	PC0093-000
Keytruda for Non-Small Cell Lu...	Keytruda	Pembrolizumab	pcodr_provfund_pembrolizumab_keytruda_nsclc_2lnbeyond.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_ptfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_coi_lcc.pdf pcodr_pembrolizumab_keytruda_nsclc_fdk_clinician.pdf pcodr_pembrolizumab_keytruda_nsclc_coi_clinician.pdf	Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 21, 2016	Nov 3, 2016	PC0077-000
Imbruvica for Chronic Lymphocy...	Imbruvica	Ibrutinib	pcodr-provfund_ibrutinib_imbruvica-cll-sll-preun.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_rec.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_cgr.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_egr.pdf pcodr_ibrutinib_imbruvica_cll-sll_in_rec.pdf pcodr_ibrutinib_imbruvica_cll-sll_pagfdk.pdf pcodr_ibrutinib_imbruvica_cll-sll_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_cllpag.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_cllpag.pdf pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_lc.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_lc.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_clinician.pdf	Chronic Lymphocytic Leukemia (previously untreated)	Reimburse with clinical criteria and/or conditions	Complete	Apr 20, 2016	Nov 3, 2016	PC0085-000
Imbruvica for Waldenström’s Ma...	Imbruvica	Ibrutinib	pcodr-provfund_ibrutinib_imbruvica-wm.pdf pcodr_ibrutinib_imbruvica_wm_fn_rec.pdf pcodr_ibrutinib_imbruvica_wm_fn_cgr.pdf pcodr_ibrutinib_imbruvica_wm_fn_egr.pdf pcodr_ibrutinib_imbruvica_wm_in_rec.pdf pcodr_ibrutinib_imbruvica_wm_pagfdk.pdf pcodr_ibrutinib_imbruvica_wm_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_wm_ptfdk_cord.pdf pcodr_ibrutinib_imbruvica_wm_ptfdk_lc.pdf pcodr_ibrutinib_imbruvica_wm_coi_lc_cord.pdf	Waldenstrom's Macroglobulinemia	Do not reimburse	Complete	Apr 21, 2016	Nov 3, 2016	PC0082-000
Vedolizumab	Entyvio	Vedolizumab	cdr_SR0487_Entyvio.pdf SR0487_complete_Entyvio-Oct-31-16.pdf SR0487_Entyvio_CL_Report.pdf SR0487_Entyvio_PE_Report.pdf SR0487_Entyvio_PI_Submissions.pdf	Crohn's disease	Reimburse with clinical criteria and/or conditions	Complete	Apr 27, 2016	Oct 31, 2016	SR0487-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 551 - 575 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Screening and Treatment of Obstetric Anemia: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1216 - Screening and treatment of obstetric anemia Final.pdf	Dec 6, 2019	Summary with Critical Appraisal	Completed	RC1216-000
Biopsy for Adults with Suspected Skin Cancer: A Rapid Qualitative Review	Biopsy for Adults with Suspected Skin Cancer: A Rapid Qualitative Review	Nov 21, 2019	Rapid Review	Completed	RC1215-000
Dosing and Timing of Immuno-Oncology Drugs	ho0008-dosing-timing-immuno-oncology-drugs.pdf	Nov 21, 2019	Technology Review	Completed	HO0008-000
Prostatectomy for People with Prostate Cancer: A Rapid Qualitative Review	Prostatectomy for People with Prostate Cancer: A Rapid Qualitative Review	Nov 12, 2019	Summary with Critical Appraisal	Completed	RC1209-000
Genome-Wide Sequencing: Ethical Considerations	he0020-genonme-wide-sequencing-protocol.pdf he0020-genome-wide-sequencing-ethical-considerations.pdf	Nov 12, 2019	Technology Review	Completed	HE0020-000
Healthy Aging		Oct 31, 2019			ES0342-000
Screening and Diagnostic Services for People at Risk of Breast Cancer: A Rapid Qualitative Review	Screening and Diagnostic Services for People at Risk of Breast Cancer: A Rapid …	Oct 31, 2019	Rapid Review	Completed	RC1208-000
Hemin for Injection (Panhematin): Budget Impact Analysis	ob0006_porphyria-report-redacted-final.pdf	Oct 16, 2019		Completed	OB0006-000
Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines	RC1190 RRMS Second-line therapy Final.pdf	Sep 26, 2019	Summary with Critical Appraisal		RC1190-000
Collaboration in Health Technology Assessment in Canada: An Environmental Scan		Sep 13, 2019	Environmental Scan	Completed	ES0329-000
Hemlibra (Emicizumab): Economic Review Report	ob0005-emicizumab-eeconomic-report.pdf	Sep 11, 2019		Completed	OB0005-000
Collaboration in Health Technology Assessment in Canada		Sep 6, 2019	Environmental Scan	Completed	ES0329-000
Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma		Aug 15, 2019	Optimal Use	Completed	CT0002-000
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations		Aug 15, 2019		Completed	CT0002-000
Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1150 Suboxone vs.pdf	Jul 31, 2019	Summary with Critical Appraisal	Completed	RC1150-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease	ho0003-he0018-ibd-ou360.pdf	Jun 6, 2019	Technology Review	Completed	HO0003-000 - HE0018-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease		Jun 5, 2019	Technology Review	Completed	HO0003-000 - HE0018-000
Criteria for conducting Environmental Assessments in CADTH HTAs		Jun 5, 2019		In Progress	MG0017-000
Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1111 Buprenorphine for Opioid Use Disorder During Pregnancy Final.pdf	May 9, 2019	Summary with Critical Appraisal	Completed	RC1111-000
Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	May 3, 2019	Rapid Review	Completed	RC1104-000
Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Apr 30, 2019	Rapid Review	Completed	RC1097-000
Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1092 Buprenorphine for OUD Final.pdf	Apr 24, 2019	Summary with Critical Appraisal	Completed	RC1092-000
Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review	Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review	Apr 18, 2019	Summary with Critical Appraisal	Completed	RC1099-000
Health Technology Reassessment: An Overview of Canadian and International Processes		Mar 22, 2019			ES0334-000
Environmental Scan on Health Technology Reassessment Processes		Mar 22, 2019			ES0334-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 551 - 575 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
deucravacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Oct 25, 2023	Reimbursement Review		Complete	SR0756-000
brentuximab vedotin		Oct 25, 2023	Reimbursement Review		Withdrawn	PC0311-000
avacopan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Oct 20, 2023	Reimbursement Review		Complete	SR0732-000
Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus Outcomes in Infants	Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus …	Oct 19, 2023	Health Technology Review	Technology Review	Completed	HE0045-000
Semaglutide 2 mg for Type 2 Diabetes	Semaglutide 2 mg for Type 2 Diabetes	Oct 19, 2023	Health Technology Review	Rapid Review	Completed	RC1507-000
Point of Care Ultrasound for Guided Central Venous Catheter Insertion	Point of Care Ultrasound for Guided Central Venous Catheter Insertion	Oct 16, 2023	Health Technology Review	Rapid Review	Completed	RC1509-000
Post–COVID-19 Condition Treatment and Management: Rapid Living Scoping Review		Oct 12, 2023	Health Technology Review	Scoping Review	Living Review	RE0040-000/RE0040-004
Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain	Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain	Oct 11, 2023	Health Technology Review	Rapid Review	Completed	RC1504-000
IV Acetaminophen for Acute Pain in Emergency Departments	IV Acetaminophen for Acute Pain in Emergency Departments	Oct 6, 2023	Health Technology Review	Rapid Review	Completed	RC1508-000
Perspectives and Experiences Regarding the Impacts of Emergency Department Overcrowding	Perspectives and Experiences Regarding the Impacts of Emergency Department Over…	Sep 28, 2023	Health Technology Review	Technology Review	Completed	HC0067-000
CADTH Pharmaceutical Reviews Update — Issue 41		Sep 28, 2023	Reimbursement Review	Pharmaceutical Review Update
rimegepant		Sep 27, 2023	Reimbursement Review		Withdrawn	SR0797-000
Optimizing the Use of Iodinated Contrast Media: Conservation Strategies Used Across Canada During the 2022 Shortage	CM0001-ICM-Conservation-Strategies.pdf	Sep 20, 2023	Health Technology Review	CMII Service	Completed	CM0001-000
Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection	Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection	Sep 20, 2023	Health Technology Review	Rapid Review	Completed	RC1502-000
Midline and Extended Dwell Catheters for IV Antibiotics	Midline and Extended Dwell Catheters for IV Antibiotics	Sep 18, 2023	Health Technology Review	Rapid Review	Completed	RC1505-000
Non-Sterile Glove Use	Non-Sterile Glove Use	Sep 15, 2023	Health Technology Review	Rapid Review	Completed	RC1499-000
Somatropin for Short Stature	Somatropin for Short Stature	Sep 15, 2023	Health Technology Review	Rapid Review	Completed	RC1501-000
trastuzumab deruxtecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Sep 15, 2023	Reimbursement Review		Complete	PC0305-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Inpatient Setting	Summary Report — September 2023 Systematic Review — September 2023	Sep 13, 2023	Health Technology Review	Systematic Review	Completed	RE0048-000
Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19	Systematic Review — September 2023 Summary Report — September 2023	Sep 13, 2023	Health Technology Review	Systematic Review	Completed	RE0049-000
Nirmatrelvir-Ritonavir (Paxlovid) for the Treatment of COVID-19	Systematic Review, September 2023 Summary Report, September 2023	Sep 12, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0042-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Outpatient Setting	Systematic Review — September 2023 Summary Report — September 2023	Sep 12, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0041-000
abiraterone acetate and prednisolone	Recommendation and Reasons Stakeholder Input Stakeholder Feedback on Draft Recommendation Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report	Sep 11, 2023	Reimbursement Review		Complete	PX0291-000 - PC0291-000
dapagliflozin	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Sep 8, 2023	Reimbursement Review		Complete	SX0749-000 - SR0749-000
abiraterone, prednisone, docetaxel	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Sep 8, 2023	Reimbursement Review		Complete	PX0298-000 - PC0298-000